Bayer Sues Major COVID-19 Vaccine Makers Over Alleged mRNA Technology Patent Infringement
核心洞察
Bayer has filed federal lawsuits against Pfizer, BioNTech, and Moderna in Delaware, alleging unauthorized use of mRNA (搜索) stabilization technology originally developed by Monsanto (搜索) in the 1980s for crop applications.
The pharmaceutical giant claims the companies misappropriated technology designed to strengthen mRNA (搜索) in crops and applied it to stabilize genetic material in their COVID-19 (搜索) vaccines.
Bayer is seeking unspecified monetary damages but emphasizes it has no intention of halting vaccine production, with Pfizer/BioNTech reporting over $3.3 billion in 2024 vaccine revenue.
Pharmaceutical giant Bayer has launched a series of federal lawsuits against leading COVID-19 (搜索) vaccine manufacturers, alleging the unauthorized use of proprietary mRNA (搜索) technology originally developed decades ago for agricultural applications. The legal actions target Pfizer, BioNTech, and Moderna in Delaware federal court, while a separate suit has been filed against Johnson & Johnson in New Jersey.
Patent Disputes Center on 1980s Agricultural Innovation
The lawsuits claim that the vaccine manufacturers copied technology developed by Bayer's subsidiary Monsanto (搜索) in the 1980s. According to Bayer's complaints, Monsanto scientists made significant advancements in reducing mRNA (搜索) instability for pest-resistant crops during that decade. This pioneering work was originally designed to strengthen mRNA in crops for stability, but Bayer alleges it was subsequently applied to stabilize the genetic material within COVID-19 (搜索) vaccines.
"The companies misappropriated technology that Monsanto (搜索), which is now part of Bayer, initially developed in the 1980s to stabilize mRNA (搜索) in crops," a Bayer spokesperson revealed, emphasizing the company's decision to pursue legal action over these patent disputes.
Financial Stakes and Market Impact
The financial context surrounding these lawsuits is substantial. Pfizer and BioNTech reported over $3.3 billion in revenue from global sales of their vaccine Comirnaty in 2024, while Moderna earned $3.2 billion from its Spikevax. Johnson & Johnson, which ceased US sales of its vaccine in 2023, faces allegations related to a DNA-based manufacturing process that Bayer claims infringes its patents.
Despite the legal actions, Bayer has clarified its position regarding vaccine availability. The company emphasized it has no intention of impeding vaccine production but seeks monetary compensation for the alleged patent infringement. Bayer, which was not involved in developing or selling COVID-19 (搜索) vaccines, is seeking unspecified monetary damages through these legal proceedings.
Complex Web of COVID-19 Patent Litigation
These lawsuits contribute to an already intricate web of patent disputes surrounding COVID-19 (搜索) vaccines, highlighting the intense competition and innovation that characterized vaccine development during the pandemic. The legal actions add another layer to existing patent litigation in the sector, including ongoing disputes between Moderna and Pfizer over vaccine-related intellectual property.
The cases underscore how agricultural biotechnology innovations from the 1980s have found unexpected applications in modern vaccine development, raising complex questions about patent scope and the evolution of mRNA (搜索) technology across different industries.